In hypothyroid patients altered microvascular structure and function may affect mood and cognitive function. We hypothesized that adult male hypothyroid (H) rats will have significantly lower forebrain blood vessel densities (BVD) than euthyroid (E) rats, and that treatment with DITPA (D) -(a thyroid hormone analogue) or T4 (T) will normalize BVD's. The E group received no thyroidectomy or treatment. The other three groups received thyroidectomies and pellets. The H group received a placebo pellet, the D group received an 80mg DITPA-containing pellet, and the T group received a 5.2mg T4 slow release pellet for 6 weeks. Body weights (BW), cardiac function, and body temperatures (BT) were measured. A monoclonal anti-platelet endothelial cell adhesion antibody was used to visualize blood vessels. The E group averaged BW's of 548 ±54g, while the H group averaged BW of 332 ± 19g (p-value < 0.001).
Introduction
Hypothyroidism is a relatively common disorder affecting about 5% of adults and 15% of older women (2, 10) . Consequences of hypothyroidism in adults include fatigue, cold intolerance, exertion, cognitive and mood dysfunction, decreased body temperature, elevated levels of triglycerides and cholesterol, hoarseness, sleep apnea and cardiovascular dysfunction (2, 14, 29) .
Although less investigated, hypothyroidism may also decrease blood vessel density, which in turn decreases delivery of oxygen and nutrients to tissues. Since hypothyroidism may depress ventilation, leading to hypoxemia (26) , the consequences of decreased blood vessel density could be enhanced in hypothyroid patients who have cardiac disease or suffer from sleep apnea and exacerbate altered cognition, mood disturbances, and fatigue.
Thyroid hormone supplementation directly affects the cardiovascular system to increase cardiac contractile function and hypertrophy, as well as cause vasodilatation (17) . Recent studies indicate that thyroid supplementation also may increase blood vessel density by acting on membrane receptors, (integrin HVI3) that interact with the mitogen-activated protein kinase (MAPK) pathway to stimulate the production of vascular endothelial growth factor (VEGF) (19) Using a chick chorioallantoic membrane model, Mousa and colleagues (19) demonstrated that nanamolar concentrations of the thyroid hormone analogue,3,5-diiothyroprionic acid (DITPA) increased mean vessel branching to the same extent as thyroxine (T4). Blocking the integrin receptor, MAPK, or T4 binding to its receptor, prevented the effects of DIPTA and T4 on blood vessel proliferation.
David and Nathaniel (8) investigated the effects of hypothyroidism on vascular density in the brain of neonatal rats. The investigators noted a significant decrease in brain blood vessel numbers in hypothyroid animals relative to controls. More recently, Gabrichidze and coworkers (12) reported the effects of local blood flow in the hippocampus and cerebellar cortex of rats made hypothyroid during development by feeding the dams an iodine deficient diet. In one month old hypothyroid offspring rats, blood flow in the dorsal hippocampus was 19% lower and 14% lower in the cerebellar cortex compared to those of age matched euthyroid rats. Both studies examined effects of prenatal hypothyroidism. Effects of hypothyroidism on blood vessel density in brains of adult rats have not been examined.
The purpose of the present study was to evaluate the effects of treating thyroidectomized rats with T4 and DITPA for six weeks on blood vessel density in forebrain regions. We hypothesized that thyroidectomy would decrease blood vessel density and that supplementation of thyroidectomized rats with DITPA or T4 ameliorate this decrease. To test the efficacy of the treatments, body temperature, body weights, cardiac function, and serum levels of T3 and T4 were also evaluated.
Methods
Male Sprague Dawley rats were obtained from Charles River Laboratories (Wilmington, MA) at approximately 10.5 weeks of age. Some rats had undergone a thyroidectomy with parathyroid reimplantation by the supplier.
Those rats that did not undergo thyroidectomy served as euthyroid controls (N=7). The thyrodectomized animals were divided into three groups. The placebo group was implanted with a placebo pellet (N=7). The T4 group (N=7) received a slow release 60-day pellet containing 5.2 mg of T4 and the DITPA group (N=5) was implanted with a 60 day slow release pellet containing 80 mg of DITPA. Pellets were prepared by Innovative Research of America (Sarasota, FL) and DITPA was kindly provided by Dr. Eugene Morkin from the University of Arizona, Tucson. The doses for DITPA and T4 were determined from pilot studies in Sprague Dawley rats that were based upon previous results from a hamster study using these pellets (17) . All procedures on living animals were approved by the USD Animal Care and Use Committee.
To access the effects of the treatments on body temperature, rectal temperature was measured under anesthesia before sacrificing the animal six weeks after receiving the pellets (at approximately 18 weeks of age). Trunk blood was collected from deeply anesthetized rats, separated into serum aliquots and frozen. T3 and T4 levels were measured with a solid-phase competitive ELISA kits according to the manufacture's protocol (T3 kit Bio-Quant, San Diego, CA; T4 kit Diagnostic Systems Laboratories, Inc. Webster, TX).
To determine the effects of hypothyroidism and T4 and DITPA treatments on cardiac function, rats underwent echocardiography prior to sacrifice. Rats were anesthetized with 1.5% isoflurane, their chests shaved and echocardiographic gel applied to the left hemithorax. To record echocardiographic data, a HP Sonos 2000 echocardiographic machine with a 7.5 MHz probe was utilized. The probe was placed on the gelled area and two dimensional M-mode echocardiograms were obtained to evaluate left ventricular dimensions, heart rate, and posterior wall thickness.
To evaluate the blood vessel density, five animals per group were perfused through the aorta with cold saline and then with 4% buffered paraformaldehyde. Brains were removed and post fixed for 5 to 6 hours in the paraformaldehyde and then placed in a 30% solution of sucrose in 0.1 M phosphate buffer (PB).
Blood vessel density was determined using immunohistochemistry for the endothelial maker endothelial cell adhesion molecule-1 or CD31 using modifications of methods described by Newton and colleagues (21) . Briefly, twenty micrometer slices from forebrain regions (0.48 to -0.28 relative to Bregma according to Paxinos and Watson(23) ) were cut using a Leica cryostat. Slices After an overnight incubation at room temperature, slices were washed 3 times for 5 minutes and incubated at room temperature with biotinylated goat anti-mouse secondary antibody, rat adsorbed (1:400, Vector) for one hour.
Following three rinses for 5 minutes each in PBS, the slices were incubated in Avidin:Biotinylated enzyme complex (ABC) for one hour at room temperature.
After rinsing the slices three times for five minutes in PB, the slices were stained with 3.3'diaminobenzidine (DAB) containing 0.01% hydrogen peroxide for 10 minutes. The slices were then rinsed in PB, let dry, and dehydrated in solutions containing increasing concentrations of alcohol, dipped in Histochoice for 15 seconds and then coverslipped with Permount.
To determine blood vessel density, four sections with areas of 3.44 mm 2 for each slice were selected in forebrain regions corresponding to barrel field, fore limb and jaw region and primary motor cortex and hindlimb regions according to the rat brain atlas of Paxinos and Watson (23) . Image J (25) was used to count the number of blood vessels in each of these sections. The density was calculated as the number of vessels per area. There was no difference in density in the four regions and an average value per animal was used to represent the vessel density. Animal identity was coded and only disclosed after all animals had been evaluated.
Data were analyzed to determine the effects of thyroidectomy comparing thyroid hormone levels, body temperatures, weights, and vessel densities between the euthyroid and placebo-treated thyrodectomized animals using an unpaired Student's t test. To compare the effects of DITPA, orT4 to the euthyroid data, a one way ANOVA was used with post hoc Dunnett's test with corrections for multiple comparisons. StatMost (Dataxiom Software Inc, Los Angeles, CA) was used to conduct the statistical analyses. Significance was accepted at P<0.05.
Results

Thyroid hormone levels
T3 levels were significantly lower in placebo relative to euthyroid group (P<0.0001, Table 1 ). In contrast the ANOVA showed no differences between the euthyroid, T4 and DITPA groups. In placebo-treated rats T4 levels were significantly lower than those of euthyroid rats (P<0.0001). The ANOVA indicated group differences in T4 levels among the DITPA, T4 and the euthyroid groups.
Supplementation of thyroidectomized rats with T4 caused a significantly higher level of plasma T4 compared to that in the euthyroid group (P=0.02). By contrast, T4 levels were significantly lower in the DIPTA group relative to the euthyroid group (P<0.0001).
Body weights
Body weights of the thyroidectomized-placebo treated rats were significantly lower than those of the euthyroid controls (P<0.001, Figure 1 ). One way ANOVA indicated that there were significant differences among the euthyroid, DITPA and T4 groups (F 2, 16 =0.02). Specifically, the DITPA group had lower body weights relative to the euthyroid group (P<0.05), but there was no difference in body weight between the euthyroid and T4-treated groups.
Body Temperatures
Body temperatures were significantly lower in the placebo group relative to the euthyroid group (P=0.0013, Figure 2 ). The one way ANOVA indicated that there was a significant effect of treatment among the euthyroid, T4 and DITPA groups (F2, 16 =10.73, P=0.0011). Specifically the DITPA group exhibited significantly lower body temperatures than either the euthyroid or the T4 treated group (P<0.02 for each).
Echocardiographic data
Relative to euthyroid control rats placebo-treated thyroidectomized rats showed lower heart rates (P=0.01), smaller left ventricular diastolic diameters (LVIDd, P =0.008) and smaller posterior wall thickness during systole and diastole (PWTs; P=0.0009), PWTd; P=0.035), Table 2 ). Moreover, heart rates of the DITPAtreated rats was significantly lower than those of the T4-treated animals (P=0.007). By contrast, there was no significant difference of LVIDs, or PWRd in thyroidectomized rats treated with T4 or DITPA relative to euthyroid controls. PWTs were still less in these two groups relative to control (P<0.04). There were no significant differences between placebo-treated thyroidectomized and euthyroid rats or thyroidectomized T4 or DITPA-treated rats in left ventricular ejection fraction or LVIDs. Figure 4 summarizes that blood vessel data. There were significantly fewer blood vessels found in the placebo group relative to the euthyroid group (P=0.0126).
Blood vessel density
Moreover, there were no significant differences in blood vessel density among the euthyroid, DITPA, and T4 groups. Thus, treatments with either T4 or DITPA prevented the decrease of forebrain blood vessel density noted in thyroidectomized rats that received placebo pellets.
Discussion
This study indicated that although rats treated with DITPA had lower body weights and body temperatures than those of euthyroid rats, blood vessels densities were comparable to those of euthyroid animals. Cardiac function, for the most part, was normalized in both T4 and DITPA-treated thyroidectomized rats. Moreover, in the T4-treated rats, T4 plasma levels were higher than in the euthyroid group, but body temperature, body weights and blood vessel density were similar to those in the euthyroid group. DITPA and T4 treatments restored blood vessel densities in forebrain regions to levels noted in euthyroid rats.
The decrease of body weight observed in the thyroidectomized rats has been reported previously (3) and may be the result of decreased levels of growth hormone (22) that were reversed by thyroxine replacement (5).
Interestingly, DITPA-treated thyroidectomized rats in the present study exhibited lower body weights and body temperatures suggesting that although DITPA did not act through the same mechanisms as thyroid hormones that bind to thyroid receptors(13).
Hypothyroidism is a risk factor for the development of cardiovascular disease (29). In an animal model of dilated cardiomyopathy, the TO-2 hamster, that also exhibits subclinical hypothyroidism, Kuzman and coworkers (17) recently reported that DITPA and T4 treatments improved, but did not normalize cardiac function. DITPA did normalize myocyte cross-sectional area. Both DITPA and T4 treatments, however, normalized cardiac blood flow at baseline conditions and after administration of adenosine. The mechanism responsible for the increased blood flow following T4 and DITPA treatment may be associated with increased levels of fibroblast growth factor 2. In another study, Wang and coworkers (30) noted that in normal Sprague Dawley rats short term DITPA administration increased vascular endothelial growth factor, basic fibroblast growth factor, amgiopoietin-1 and Tie-2, but an increase in capillary density was not noted. However, work done by the same group (32), in a postinfacrtion rat model showed that DITPA treatment was able to increase arteriolar length density in septum when the infarct size was greater than 50%. Thus, DITPA treatment may improve myocardial blood vessel development in animal models with cardiovascular impairments.
Dagre and coworkers (7) found abnormal endothelial function in patients exhibiting either overt hypothyroidism or subclinical hypothyroidism. The duration of reactive hyperemia was decreased with increasing levels of thyroid stimulating hormone (TSH) levels. In a hypothyroid group treated with T4, reactive hyperemia durations were comparable to those of euthyroid control subjects.
The authors suggested that a decreased production of nitric oxide in hypothyroid patients may be responsible for their diminished vascular responses.
Moreover, increased nitric oxide is associated with angiogenesis (4).
Another factor associated with angiogenesis is increased levels of vascular endothelial growth factor (VEGF). In a recent study Dedecjius and coworkers (9) evaluated poor-platelet plasma VEGF levels in hypothyroid patients before and after two months of treatment with T4. Prior to treatment, VEGF levels were significantly reduced in the hypothyroid patients relative to that in the controls. Following treatment with T4, VEGF levels in the hypothyroid patients were comparable to those of euthyroid controls. Although the authors did not measure blood vessel density, they suggested that the increase in VEGF levels may improve blood vessel density in patients.
Constant and coworkers (6) measured cerebral blood flow (CBF) in patients who underwent a thyroidectomy for thyroid cancer and were hypothyroid for 4-5 weeks and then following thyroid hormone replacement. In addition psychometric and cerebral glucose metabolism was measured in these patients. During hypothyroidism, CBF was decreased 23.4% whereas glucose metabolism was decreased 12.1% relative to patients in the euthythroid state. In addition, when hypothyroid, patients showed more anxiety, depression and psychomotor retardation.
In another study in mildly hypothyroid patients before and after treatment, Krausz and coworkers (16) These studies support our findings that decreasing thyroid hormone levels could result in decreased blood vessel densities. Thyroid hormones can act on both membrane bound or cytoplasmic receptors to affect blood vessel densities. Mousa and coworkers (19) using a chick chorioallantoic membrane model indicated that administration of both T4 unbound and bound to agarose (which prevented transport of T4 into the cell) increased blood vessel growth relative to a PBS control. Moreover, they determined that DITPA had the same effect as the two preparations of T4 used in that experimental design.
Combining DITPA and an integrin HvI3 inhibitor or DITPA and tetrac, an inhibitor of T4 binding to membrane receptors, prevented the angiogenic effects of DITPA. These studies and the ones presented in this paper suggest that T4 and DITPA may promote angiogenesis.
Induction of angiogenesis may be beneficial in a number of disorders. For example in conditions of ischemia, stroke, and heart disease, and subclinical hypothyroidism increased blood vessel density may improve perfusion of brain and systemic tissues improving cognitive and functional capabilities (4, 7, 11, 17) . Administration of T4, aside from its angiogenic effect, may have some potentially adverse effects such as increased metabolic rate and increased sympathetic nervous system stimulation (27, 28) . In contrast, DITPA has been shown to have beneficial effects on cardiovascular function, improve adverse chamber and myocyte remodeling, and improve myocardial blood flow in hamsters with dilated cardiomyopathy (15) .
Another mechanism by which hypothyroidism may affect cardiovascular function and angiogenesis is by increasing angiotensin II receptor levels.
Recently, Carneiro-Ramos and coworkers(3) evaluated angiotensin receptors (AT and AT2) levels in hypothyroid rat hearts. Although serum levels of angiotensin II were not elevated in the hypothyroid rats, AT1 receptor expression was. Moreover, Muzenmaier and Greene (20) showed that rat brain blood vessel was increased by blocking AT1 receptors, but not by blocking angiotensin converting enzyme. Whether AT1 receptor levels are increased in the brains of hypothyroid rats needs to be determined.
Recent studies in the brain also indicate that factors promoting angiogenesis may also enhance neurogenesis (24) . Hypothyroidism can reduce normal neurogenesis in rat dentate gyrus by 30% (18) . Thyroid hormone supplementation not only increased the number of neurons, but also improved 
Perspectives and significance
This study indicated that hypothyroidism in rats induces a decrease in brain blood vessel density that can be modulated by DITPA and thyroxine replacement. Future studies are needed to determine the underlying mechanisms responsible for these effects. Since thyroid hormone status affects not only blood vessels, but also other cell types on the brain including neurons, astrocytes and oligodendrocytes, more inclusive studies are required to understand how this relatively common disorder can affect the quality of life of patients who suffer not only from outright hypothyroidism, but also from subclinical hypothyroidism. Finally, since not all treated hypothyroid patients show full recovery (16, 31) , the efficacy of hormone replacement in reversing these dysfunctions needs to be clarified. Table legends 1. The data are in means ± SD. Different superscripted letters denote significant differences (P<0.05) among groups for each hormone. Values are means ± SD. Asterisks denote differences (P<0.05) relative to the control (euthyroid) group values. There was a significant difference between DITPA and T4 groups (P<0.05) in heart rate as indicated by †. The data are in means ± SD. Different superscripted letters denote significant differences (P<0.05) among groups for each hormone.
